Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia

Subjects

Subjects :

Adult
Male
Chronic lymphocytic leukaemia
Cancer Research
COVID-19 Vaccines
Chronic lymphocytic leukemia
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Antibodies, Viral
Persistence (computer science)
Correspondence
medicine
Humans
In patient
Longitudinal Studies
Prospective Studies
Prospective cohort study
BNT162 Vaccine
Aged
Preventive medicine
Aged, 80 and over
Messenger RNA
biology
SARS-CoV-2
business.industry
Case-control study
COVID-19
Hematology
Middle Aged
Prognosis
medicine.disease
Leukemia, Lymphocytic, Chronic, B-Cell
COVID-19 Drug Treatment
Oncology
Case-Control Studies
Antibody Formation
Immunology
biology.protein
Female
Antibody
business
Follow-Up Studies

Details

ISSN :

14765551 and 08876924

Volume :

35

Database :

OpenAIRE

Journal :

Leukemia

Accession number :

edsair.doi.dedup.....ba84962e2cfb6835e1502073d6c6fb22